86456-97-5

Basic information

• Product Name: 3-ETHOXY-4-METHOXYPHENETHYLAMINE
• Synonyms: 2-(3-Ethoxy-4-methoxyphenyl)ethanamine;RARECHEM AL BW 0613;3-ETHOXY-4-METHOXYPHENETHYLAMINE;AKOS 233-100;3-ETHOXY-4-METHOXYPHENETHYLAMINE 99%;NISTC86456975
• CAS NO: 86456-97-5
• Molecular Formula: C₁₁H₁₇NO₂
• Molecular Weight: 195.26
• Mol File: 86456-97-5.mol

Chemical Properties

• Boiling Point: 119 °C
• Flash Point: 144.1°C
• Appearance: /
• Density: 1,05 g/cm3
• Vapor Pressure: 0.00154mmHg at 25°C
• Refractive Index: 1.513
• PKA: 9.74±0.10(Predicted)
• CAS DataBase Reference: 3-ETHOXY-4-METHOXYPHENETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ETHOXY-4-METHOXYPHENETHYLAMINE(86456-97-5)
• EPA Substance Registry System: 3-ETHOXY-4-METHOXYPHENETHYLAMINE(86456-97-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT, IRRITANT-HARMFUL
• Hazardous Substances Data: 86456-97-5(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research:
3-ETHOXY-4-METHOXYPHENETHYLAMINE is used as a research chemical for studying its chemical and biological properties. It aids in understanding the structure-activity relationships of phenethylamine derivatives and their potential interactions with biological systems.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3-ETHOXY-4-METHOXYPHENETHYLAMINE is used as a key precursor in the synthesis of various drugs. Its unique structure allows for the development of new compounds with potential therapeutic benefits.
Used in Psychoactive Drug Synthesis:
3-ETHOXY-4-METHOXYPHENETHYLAMINE is also employed as a precursor in the synthesis of psychoactive drugs. Its ability to modulate neurotransmitter systems makes it a valuable compound for exploring the effects of psychoactive substances on the human brain.
Note: The specific applications and industries for 3-ETHOXY-4-METHOXYPHENETHYLAMINE are not provided in the materials. The uses listed above are inferred based on its classification as a phenethylamine derivative and its role as a precursor in pharmaceutical and psychoactive drug synthesis. Further information may be required to provide more detailed applications in specific industries.

InChI:InChI=1/C11H17NO2/c1-3-14-11-8-9(6-7-12)4-5-10(11)13-2/h4-5,8H,3,6-7,12H2,1-2H3

Upstream product

• 857813-55-9 3-(3-ethoxy-4-methoxy-phenyl)-propionic acid ethyl ester 
• 64-17-5 ethanol 
• 91134-29-1 3-ethoxy-4-methoxy-β-nitro-styrene 
• 64-19-7 acetic acid 
• 858214-38-7 3-(3-ethoxy-4-methoxy-phenyl)-propionic acid amide 
• 103796-99-2 (3-ethoxy-4-methoxy-phenyl)-acetonitrile 
• 31282-89-0 3-(3-ethoxy-4-methoxy-phenyl)-propionic acid 
• 147730-26-5 3-ethoxy-4-methoxy-benzyl alcohol 
• 93517-17-0 2-ethoxy-4-chloromethyl-1-methoxy-benzene 

Downstream Products

• 861056-33-9 (3,4-dimethoxy-phenyl)-acetic acid-(3-ethoxy-4-methoxy-phenethylamide) 
• 857543-45-4 benzo[1,3]dioxol-5-yl-acetic acid-(3-ethoxy-4-methoxy-phenethylamide) 
• 115208-48-5 (4-benzyloxy-phenyl)-acetic acid-(3-ethoxy-4-methoxy-phenethylamide) 
• 439146-82-4 6-ethoxy-7-methoxy-1-methyl-3,4-dihydro-isoquinoline 
• 6272-95-3 6-ethoxy-7-methoxy-1,2-dimethyl-3,4-dihydro-isoquinolinium; chloride 
• 76353-57-6 6-ethoxy-7-methoxy-1-veratryl-isoquinoline 

Relevant articles and documents

Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein and its deficiency markedly enhanced the survival rate of patient with cardiovascular diseases (CVDs). Forty berberine (BBR) derivatives were synthesized and evaluated for their activities on down-regulating the transcription of PCSK9 in HepG2 cells, taking BBR as the lead. Structure–activity relationship (SAR) analysis revealed that 2,3-dimethoxy moiety might be beneficial for activity. Among them, 9k displayed the most potent activity with IC50 value of 9.5 ± 0.5 μM, better than that of BBR. Also, it significantly decreased PCSK9 protein level at cellular level, as well as in the liver and serum of mice in vivo. Furthermore, 9k markedly increased LDLR expression and LDL-C clearance via down-regulating PCSK9 protein. The mechanism of action of 9k is targeting HNF1α and/or Sp1 cluster modulation upstream of PCSK9, a different one from BBR. Therefore, 9k might have the potential to be a novel PCSK9 transcriptional inhibitor for the treatment of atherosclerosis, worthy for further investigation.